[Resistance to treatment in movement disorders].
Therapeutic strategies for essential tremor (ET) and Parkinson's disease (PD) can be divided into two successive steps, one based on oral medications and the other, more invasive, using pumps or functional neurosurgery. When ET becomes refractory to propranolol, primidone and other, second-choice compounds, deep brain stimulation of the VIM nucleus of the thalamus can be considered. When PD becomes resistant to dopamine replacement therapy using various combinations of dopaminergic agents, then three options can be discussed: first, a subcutaneous apomorphine mini-pump, second, a jejunal levodopa-delivery system by means of percutaneous gastrostomy, and third, bilateral deep brain stimulation of the subthalamic nucleus. The above interventions are successful in about 80% of cases.
Service de neurologie, DNC, CHUV-UNIL, 1011 Lausanne. francois.vingerhoets@chuv.ch
François J G
FJ
Vingerhoets
Pierre R
PR
Burkhard
D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001058:Apomorphine / Q000008:administration & dosage / Q000627:therapeutic use; D046690:Deep Brain Stimulation / Q000379:methods / Q000523:psychology / Q000706:statistics & numerical data; D004351:Drug Resistance / Q000502:physiology*; D020329:Essential Tremor / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D009069:Movement Disorders / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D009493:Neurosurgery / Q000379:methods; D010300:Parkinson Disease / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D017211:Treatment Failure
D000978:Antiparkinson Agents; D007980:Levodopa; D001058:Apomorphine